PRQR Stock Analysis: Buy, Sell, or Hold?
PRQR - ProQR Therapeutics N.V. Ordinary Shares
$1.81
-0.08 (-4.23%)
▼
5d:
+19.08%
30d:
+16.03%
90d:
+21.48%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When PRQR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: PRQR is 7.1% above its trading range ($1.69). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: PRQR is 7.1% above its trading range ($1.69). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: PRQR is currently trading at $1.81, which is considered extended relative to its 30-day fair value range of $1.41 to $1.69.
Technical Outlook: Technically, PRQR is showing sideways momentum. The price is approaching resistance at $1.63. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: PRQR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.88 (+390.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PRQR is showing sideways momentum. The price is approaching resistance at $1.63. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: PRQR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.88 (+390.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.41 -
$1.69
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BEARISH: Price extended above range (+7.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.2%)
- BULLISH: Trading 390.3% below Wall St target ($8.88)
Trading Range Analysis
30-Day Trading Range
$1.41 -
$1.69
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.35
Resistance Level
$1.63
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.67
Wall Street Target
$8.88
(+390.3%)
Revenue Growth (YoY)
-57.1%
Share & Embed Analysis
Last updated: June 24, 2026 5:17 PM ET
Data refreshes hourly during market hours. Next update: 6:17 PM
Data refreshes hourly during market hours. Next update: 6:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRQR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 58 HOLD |
